Close menu




October 9th, 2026 | 07:30 CEST

Deutz Stock Under Pressure! Buy Recommendations for Bayer and Partner MustGrow Biologics

  • biologicals
  • biofertilizer
  • biocontrol
  • agritech
  • mustard
  • Pharma
Photo credits: AI-Generated with ChatGPT

Created and Published on Behalf of MustGrow Biologics Corp.

What is going on with Deutz? The Cologne-based company had emerged as a favourite among investors looking to capitalize on the defence boom. But after more than doubling in just a few months, the stock has recently fallen by around 20%. There are clear reasons for the pullback—but should investors be worried? There is certainly reason for optimism at MustGrow. The US commercialization of the soil-fertility product TerraSante™ has begun, and demand is outpacing supply. Contract manufacturers now need to ramp up production quickly. Analysts expect revenues and earnings to rise sharply in the coming years. A partnership with Bayer is also expected to contribute to this growth. Bayer, meanwhile, plans to expand its US presence with a multibillion-dollar investment. The stock is not currently benefiting from this development. Nevertheless, analysts are recommending the shares as a Buy.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: MUSTGROW BIOLOGICS CORP. | CA62822A1030 | TSXV: MGRO , OTCQB: MGROF , BAYER AG NA O.N. | DE000BAY0017 , DEUTZ AG O.N. | DE0006305006

Table of contents:


    MustGrow: Analysts Expect Sharply Rising Revenues and Earnings

    GBC Research sees significant upside potential for MustGrow Biologics. In their latest update, analysts maintain their "Buy" recommendation for the Canadian AgTech company, which focuses on natural active ingredients derived from mustard seeds for agricultural use. The price target is CAD 2.51. The stock is currently trading at around CAD 0.42.

    Analysts say the investment story rests on the growing commercialization of the biofertility product TerraSante™ and the development of the pre-registered biological crop protection product TerraMG™. The company is working closely with Bayer on the latter. In the first half of 2026, MustGrow already generated CAD 1.36 million in milestone revenue from the Bayer partnership. Additional milestone payments and future licensing fees could follow.

    TerraSante™ is now approved for sale in thirteen US states. In late May 2026 alone, three additional agricultural markets—Texas, Utah, and Montana—were added. MustGrow has thus laid the foundation for further growth.

    Although MustGrow Biologics' growth is currently proceeding more slowly than originally hoped, the reason for this is entirely positive. Demand currently exceeds available production capacity. Contract manufacturers in Asia are not ramping up their facilities fast enough. However, this should change in the coming months and boost growth. By mid-August 2026, MustGrow had already generated approximately CAD 0.90 million in revenue with TerraSante™, exceeding total 2025 revenue by 46%. A large portion of sales came from existing customers, indicating strong product acceptance. According to the company, at full capacity, the existing production facilities could generate annual revenue of CAD 15 million to CAD 25 million.

    Analysts expect MustGrow to generate revenue of CAD 3.50 million in the current year. Next year, revenue is projected to reach CAD 14.05 million, and in 2028, CAD 31.56 million. For 2028, analysts forecast positive EBITDA of CAD 8.46 million. Earnings per share are projected to reach CAD 0.11. At the current share price of CAD 0.42, the market capitalization stands at around CAD 29.58 million. This is too low, according to GBC Research.

    https://youtu.be/XFGCBf1w8mg?si=E1pvtix0buQcpoN7

    Bayer Invests Billions

    While MustGrow has begun commercialization in the US, its partner, Bayer, is also expanding there. The Leverkusen-based company has announced plans to expand its US presence with a billion-dollar investment. The pharmaceutical and agrochemical group plans to invest USD 2.2 billion in a new production facility in New Albany, Ohio. Bayer is thus continuing its expansion strategy in the world's largest pharmaceutical market. Over the past five years alone, the company has invested more than USD 7 billion in pharmaceutical research, development, and production in the US. The new facility is expected to create approximately 600 highly skilled jobs. During the construction phase, Bayer anticipates employing an additional 1,500 workers.

    The new production complex will be equipped with modern digital technologies and a high degree of automation. The plan is to manufacture active pharmaceutical ingredients and finished pharmaceutical products, particularly for the treatment of cancer, cardiovascular diseases, and kidney diseases. The first production facility for active pharmaceutical ingredients is scheduled to begin operations in 2031, and a second facility for finished pharmaceutical products is planned for 2034. With this expansion, Bayer aims to strengthen its supply chains and meet the rising demand for medications in the US and other markets.

    Bayer's stock has slipped from EUR 50 to EUR 43 in recent days. Nevertheless, the year-to-date gain in 2026 stands at 14%, and over the past year, it has reached 58%. Most recently, analysts at JPMorgan have expressed a positive outlook. They recommend an "Overweight" rating on Bayer stock, with a price target of EUR 61.

    Deutz: What Is Going On?

    In recent months, Deutz has emerged as a new investor favourite in the defence sector. Since the end of June, the stock has at one point more than doubled. But recently, it has come under significant pressure. In a few weeks, it lost about 20% of its value and is now trading below EUR 11. While a correction is certainly healthy, there are also specific reasons for the sell-off.

    One trigger was the capital increase in mid-September. Deutz placed about 15.3 million new shares at EUR 11.70, raising about EUR 179 million. The placement discount and the dilution weighed on the share price. Added to this is the ongoing weakness in the traditional engine business. In particular, demand for smaller agricultural machinery engines is sluggish. According to media reports, Deutz is therefore planning further job cuts at its Cologne headquarters. By the end of 2028, it could eliminate about 200 to 300 jobs. These issues in the traditional business are dampening enthusiasm for the expansion of defence activities.

    Analysts, however, remain largely optimistic. As recently as October 7, Berenberg raised its price target for Deutz shares from EUR 13 to EUR 16.50 and reaffirmed its "Buy" recommendation. In particular, the acquisition of the Flensburg-based vehicle manufacturer FFG is expected to strengthen the military applications business and lead to higher margins in the medium term. Warburg Research is even more optimistic, with a price target of EUR 19.


    There is currently no reason to panic about Deutz. However, the Cologne-based company cannot afford any major missteps as it expands its defence business. According to analysts, MustGrow is on the cusp of a major growth phase. The stock has yet to reflect this potential. MustGrow's partner, Bayer, meanwhile, is currently making headlines primarily in the pharmaceutical business. Analysts also see potential in the Leverkusen-based company's stock.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read

    Commented by Carsten Mainitz on November 10th, 2026 | 05:45 CET

    Exciting pharma duel: Who will take off now - BioNxt Solutions, Bayer or Novo Nordisk?

    • Pharma
    • Biotech
    • Innovations
    • Diabetes

    New active ingredients, expanded indications and more user-friendly dosage forms are driving momentum in the global pharmaceutical market. BioNxt Solutions is focusing on novel oral dissolvable films and working towards regulatory and clinical breakthroughs. Industry heavyweights Bayer and Novo Nordisk have recently reported solid quarterly results. Bayer has already overcome several challenges and raised its outlook. At the same time, Novo Nordisk is impressively demonstrating how innovative forms of administration in obesity treatment can achieve soaring commercial success. Where do the most attractive opportunities for investors lie following the latest developments?

    Read